A case-control study was done by Fiandaca et al. [58] showing that blood-derived sEVs biomarkers, including P-S396-tau, P-T181-tau, and Aβ1–42 were able to detect AD up to 10 years prior to clinical onset. The gene discussed is MAPT; the disease is Alzheimer disease.